Advertisement

Follicular Thyroid Cancer and Bone Metastasis

  • Elgin Özkan
  • Çiğdem Soydal
Chapter

Abstract

A 78-year-old male patient with follicular carcinoma in the left thyroidal lobe with 10 cm diameter received radioiodine ablation treatment (RAT) with 5550 MBq (150 mCi) iodine-131 (131I) 2 months after the operation. During the RAT, the serum thyroglobulin (Tg) level was measured as 252.59 ng/ml. Radioiodine uptake in the thyroid bed and thoracal and pelvic regions was observed on a postablative whole-body scintigraphy. Simultaneous bone scintigraphy was performed. A moderately increased uptake was observed in the right iliac bone. Thoracal and pelvic computed tomographies (CTs) were also performed for further evaluation of the radioiodine uptake in thoracal and pelvic regions. A pathologic soft tissue lesion of 2.5 × 1.5 cm that may have been compatible with a lymphadenopathy on the anterior mediastinum was observed, and a sclerotic bone lesion of 2 cm in diameter that was concordant with metastasis on the right iliac bone was reported on CT. The patient was followed up for 5 years under suppressive dose of LT4 treatment. Serum Tg measurements and pelvic CT and/or MRI were performed periodically. Biochemical and radiological stabilization were detected during the 5-year follow-up period. Additional surgery or local therapy for the bone metastasis was not applied because of the asymptomatic and stable local metastatic disease.

Keywords

Follicular thyroid carcinoma Bone metastases Radioiodine 

References

  1. 1.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.CrossRefGoogle Scholar
  2. 2.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefGoogle Scholar
  3. 3.
    Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249–52.CrossRefGoogle Scholar
  4. 4.
    Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:6010–6.CrossRefGoogle Scholar
  5. 5.
    Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. Survival and therapeutic modalities in patients with bone metastasis of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:1568–73.CrossRefGoogle Scholar
  6. 6.
    Farooki A, Leung V, Tala H, Tuttle RM. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97:2433–9.CrossRefGoogle Scholar
  7. 7.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26:1–133.  https://doi.org/10.1089/thy.2015.0020.CrossRefGoogle Scholar
  8. 8.
    NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma, 2015 Version 2. 2015. NCCN.org.Google Scholar
  9. 9.
    Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–8.  https://doi.org/10.1016/S2213-8587(13)70215-8.CrossRefPubMedGoogle Scholar
  10. 10.
    Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, Kitano H, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma. Endocr J. 2016;63:597–602.  https://doi.org/10.1507/endocrj.EJ16-0064.CrossRefPubMedGoogle Scholar
  11. 11.
    Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466–70.CrossRefGoogle Scholar
  12. 12.
    Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci. 2007;104(8):2803.CrossRefGoogle Scholar
  13. 13.
    Elboğa U, Özkaya M, Sayiner ZA, Çelen YZ. Lu-177 labelled peptide treatment for radioiodine-refractory differentiated thyroid carcinoma. BMJ Case Rep. 2016.  https://doi.org/10.1136/bcr-2015-213627.
  14. 14.
    Santhanam P, Taieb D, Solnes L, Marashdeh W, Ladenson PW. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol. 2017;86:645–51.  https://doi.org/10.1111/cen.13306.CrossRefGoogle Scholar
  15. 15.
    Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M. Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1006–10.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Elgin Özkan
    • 1
  • Çiğdem Soydal
    • 2
  1. 1.Department of Nuclear MedicineMedical Faculty of Ankara UniversityAnkaraTurkey
  2. 2.Department of Nuclear MedicineAnkara University School of MedicineAnkaraTurkey

Personalised recommendations